| Literature DB >> 35698839 |
Youngji Jo1, Sourya Shrestha2, Munkhzul Radnaabaatar3, Hojun Park3,4, Jaehun Jung3,5.
Abstract
BACKGROUND: Since March 2020, when coronavirus disease 2019 (COVID-19) was declared a pandemic, many countries have applied unprecedented restrictive measures to contain the spread of the virus. This study aimed to explore the optimal social distancing policy for COVID-19 control in South Korea to safely reopen the society.Entities:
Keywords: COVID-19; ICU; Pandemic; SARS-CoV-2; Social Distancing Policy
Mesh:
Year: 2022 PMID: 35698839 PMCID: PMC9194485 DOI: 10.3346/jkms.2022.37.e189
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 5.354
Fig. 1Schematic representation of the modelling approach. We use a compartmental modelling framework to incorporate (A) natural history of COVID-19 and (B) age structure. (A) Natural history was captured by modelling transition of individuals between eight states: uninfected; susceptible, vaccinated, exposed, asymptomatic (undetected), asymptomatic (true positive), symptomatic (detected), recovered, and dead. (B) The population was subdivided into four groups based on age: 0–19 years, 20–39 years, 40–59 years, 60 years and above. Population in the four groups were modelled to have different contact patterns. As we focused on the key intervention strategies such as social distancing duration/level, testing rate and vaccination rate, we varied the parameters beta, tau, and v for respective intervention scenarios.
COVID-19 = coronavirus disease 2019.
Model input parameters
| Characteristics | Age, yr | Reference | |||||
|---|---|---|---|---|---|---|---|
| 0–19 | 20–39 | 40–59 | 60+ | ||||
| Population as of 1 Jul 2021 | |||||||
| Total population | 8,809,740 | 13,991,940 | 17,101,260 | 11,919,060 | KDCA (total population = 51,822,000) | ||
| Uninfected | 8,758,016 | 12,682,284 | 15,688,592 | 4,525,342 | Total population-infected-vaccinated-recovered-dead | ||
| Vaccinated | 724 | 1,257,656 | 1,360,168 | 7,290,718 | KDCA by 30 Jun 2021 | ||
| Exposed | 1,000 | 2,000 | 2,000 | 2,000 | Assumed by incidence level | ||
| Asymptomatic | 1,000 | 2,000 | 2,000 | 2,000 | |||
| Test positive (PCR) | 100 | 200 | 400 | 300 | KDCA | ||
| Symptomatic | 100 | 200 | 400 | 300 | KDCA | ||
| Recovered | 50,000 | 50,000 | 50,000 | 100,000 | KDCA | ||
| Dead | 0 | 0 | 500 | 1,000 | KDCA | ||
| Model parameters | |||||||
| Contact matrix | |||||||
| Age 0–19 yr | 2.3 | 0.6 | 0.5 | 0.1 | References | ||
| Age 20–39 yr | 0.7 | 1.9 | 1.0 | 0.1 | |||
| Age 40–59 yr | 0.9 | 1.2 | 1.5 | 0.2 | |||
| Age 60+ yr | 0.3 | 0.4 | 0.5 | 0.4 | |||
| Effective vaccinations per daya (%) | |||||||
| 1 Jul–20 Nov 2021 | 9,787 (0.1%) | 53,998 (0.4%) | 73,070 (0.4%) | 29,964 (0.3%) | The average number of vaccinations per day by age group from KDCA data | ||
| 21 Nov–30 Dec 2021 | 29,361 (0.3%) | 26,999 (0.2%) | 36,335 (0.2%) | 2,996 (0.3%) | Assumed age specific vaccination uptake by Jun 2022 to reach 70% effective coverage (± 20% were assumed for variation for sensitivity analyses) | ||
| 1 Jan–30 Jun 2022 | 19,574 (0.2%) | 16,199 (0.1%) | 14,614 (0.01%) | 300 (0.0%) | |||
| 1 Jul–30 Dec 2022 | 1,957 (0.0%) | 1,079 (0.0%) | 1,461 (0.0%) | 60 (0.0%) | |||
| Progression rate from (unvaccinated) asymptomatic to symptomatic status | 0.14 | 0.2 | 0.15 | 0.12 | Probability of symptoms given infection: 66% (age 0–19 years), 74% (age 20–39 years), 68% (age 40–59 years), 62% (age 60 years and over) from KDCA data | ||
| Estimated daily progression rate by the formula: Probability of Symptoms Given Infection × Recovery Rate/(1 − Recovery Rate) | |||||||
| Symptomatic case fatality risk | 0.0001 | 0.0003 | 0.002 | 0.0853 | KDCA | ||
| Vaccine effectiveness against infection (against new variants) | |||||||
| 1st dose AstraZeneca | 50% (30%) | Reference | |||||
| 1st dose Johnson & Johnson | 50% (30%) | ||||||
| 1st dose Pfizer/Moderna | 50% (35%) | ||||||
| 2nd dose AstraZeneca | 77% (66%) | ||||||
| 2nd dose Pfizer/Moderna | 95% (88%) | ||||||
| 3rd dose AstraZeneca | 80% (70%) | ||||||
| 3rd dose Pfizer/Moderna | 98% (90%) | ||||||
| Transmissibility | |||||||
| 1 Jul–15 Oct 2021 | 0.04 | Estimated by EpiEstim | |||||
| 16 Oct–21 Nov 2021 | 0.06 | ||||||
| 21 Nov 2021–30 Dec 2022 | 0.12 (0.1–0.14) | Taken by the assumption of 3 or 4 times greater transmissibility of the new variants from the average Rt estimate between 1 Jul to 21 Nov 2021 (base case) | |||||
| Social distancing control (21 Nov 2021–30 Feb 2022) | |||||||
| Weak control | General 40% reduction in transmission | References | |||||
| Moderate control | General 50% reduction in transmission | ||||||
| Strong control | General 60% reduction in transmission | ||||||
| Testing rate among asymptomatic patients (1 Jul 2021–30 Dec 2022) | 0.14 (0.11–0.17) | Estimated daily testing rate among asymptomatic patients based on the total daily testing volume | |||||
| Recovery rate | 0.07 (0.06–0.08) | 14 days | |||||
| Incubation rate | 0.33 | 3–4 days | |||||
| Diagnostic sensitivity | 0.95 | Reference | |||||
KDCA = Korea Disease Control and Prevention Agency, PCR = polymerase chain reaction.
aVaccination rates differ by age group by the government strategies and population size. The government prioritized vaccination to 60+ years age group, incrementally expanded access to 40–59, 20–39, and 0–19 years age groups.
Projected health outcome by intervention scenarios
| Scenario | Intervention policy | Health outcome | ||||||
|---|---|---|---|---|---|---|---|---|
| From 21 Nov 2021 to the next 2–4 mon | From 21 Nov 2021 to 30 Dec 2022 | From 1 Jul 2021 to 30 Dec 2022 | ||||||
| Social distancing control | Social distancing duration, mon | Testing | Vaccination | Total cumulative cases (in thousand) | Total ICU admission | Total cases averted (in thousand) | Total ICU admission averted | |
| Scenario 1 | Moderate | 3 | Base | Base | 1,737 | 2,169 | NA | NA |
| Scenario 2 | Strong | 4 | Base | Base | 410 | 403 | −1,327 | −1,766 |
| Scenario 3 | Strong | 2 | +20% | +20% | 1,032 | 978 | −705 | −1,191 |
| Scenario 4 | Weak | 4 | Base | Base | 1,374 | 1,421 | −363 | −748 |
| Scenario 5 | Weak | 2 | +20% | +20% | 2,483 | 3,257 | 746 | 1,088 |
ICU = intensive care unit, NA = not available.
Fig. 2Projected incidence of COVID-19 in South Korea between November 2021 and December 2022. The impacts of possible COVID-19 response scenarios were compared. The black dashed line indicates the time of projection (21 November 2021) and the red dashed line indicates the time of lifting social distancing control (in 2, 3, or 4 months). The pink shaded area projected results with 95% confidence intervals by varying transmissibility, testing intensity and vaccination rate. (A) Scenario 1 (base case: 3 months of moderate social distancing control with current level of testing and vaccination rates); (B) Scenario 2 (4 months of strict social distancing control with current level of testing and vaccination rates); (C) Scenario 3 (2 months of strict social distancing control with 20% increased level of testing and vaccination rates than the current rates); (D) Scenario 4 (4 months of weak social distancing control with current level of testing and vaccination rates); (E) Scenario 5 (2 months of weak social distancing control with 20% increased level of testing and vaccination rates than the current rates).
COVID-19 = coronavirus disease 2019.
Fig. 3Projecting prevalence of severe patients in South Korea between November 2021 and December 2022. The impacts of possible COVID-19 response scenarios were compared. The black dashed line indicates the time of projection (21 November 2021) and the red dashed line indicate the time of lifting social distancing control (in 2, 3, or 4 months). The pink shaded area projected results with 95% confidence intervals by varying transmissibility, testing intensity and vaccination rate. The light blue shaded area indicates the ICU capacity for COVID-19 patients in South Korea. (A) Scenario 1 (base case: 3 months of moderate social distancing control with current level of testing and vaccination rates); (B) Scenario 2 (4 months of strict social distancing control with current level of testing and vaccination rates); (C) Scenario 3 (2 months of strict social distancing control with 20% increased level of testing and vaccination rates than the current rates); (D) Scenario 4 (4 months of weak social distancing control with current level of testing and vaccination rates); (E) Scenario 5 (2 months of weak social distancing control with 20% increased level of testing and vaccination rates than the current rates).
COVID-19 = coronavirus disease 2019, ICU = intensive care unit.
Fig. 4Cumulative incidence of COVID-19 cases and the peak number of severe COVID-19 patients in South Korea between 1 July 2021 to 31 December 2022. This heat map displays the cumulative incidence of COVID-19 cases (A) and the peak number of severe COVID-19 patients (B) between 1 July 2021 to 31 December 2022. Each panel corresponds to the social distancing duration (2, 3, 4 months from 22 November 2022), social distancing control level (strong as reducing 60% transmissibility, medium as reducing 50% transmissibility, and weak as reducing 40% transmissibility), testing rate (base as the average daily testing rate between 1 July 2021 to 21 November 2021, ×0.8 as 20% decrease of the average rate, and ×1.2 as 20% increase of the average rate), and vaccination rate (base as the uptake rate by the current vaccine roll-out plan, ×0.8 as 20% decrease of the current rate, and ×1.2 as 20% increase of the average rate). Rt base corresponds to the current average transmissibility between 1 July 2021 to 21 November 2021 and Rt base ×3 and Rt base ×4 as the 3 times and 4 times increase of the current level of transmissibility from 22 November 2021 to 31 December 2022.
COVID-19 = coronavirus disease 2019, ICU = intensive care unit.